Achieve’s cytisinicline CRL cited a prior facility and incomplete labeling, not clinical failure. Why this CMC rejection ...
Viridian’s Lumvoa approval breaks Tepezza’s TED monopoly. Inside the label, Phase 3 data, safety risks, payer hurdles and ...
Unicycive OLC received a second FDA CRL over third-party manufacturing deficiencies. The case shows why CMC risk now drives ...
FDA Issues CRL to Sobi for NASP in Uncontrolled Gout, but the letter did not attack the clinical case. It attacked ...
AlzeCure did not prove ACD856 works in Alzheimer’s patients. It proved something else: early clinical safety, brain exposure, and a novel CNS mechanism can still be valuable enough to move a small ...
SigHT is formally a long-term observational study. Strategically, its timing points to something larger: Tanabe is building a ...
The CMC Execution Crisis: Why Unicycive’s OLC CRL Is a Warning Shot for Every Indian CDMO | Witfire Elite View Witfire Elite CMC & Manufacturing Case Studies CDMO Strategy Long Read Pharma Market Case ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results